What changed in McKESSON CORPORATION's latest annual report
In the year ended 31 Mar 2026, McKESSON CORPORATION's revenue rose 12.4% to USD 403.43bn, from USD 359.05bn; net income rose 44.5% to USD 4.76bn, from USD 3.29bn; cash and cash equivalents fell 30.2% to USD 3.98bn, from USD 5.69bn.
Year ended 31 Mar 2026. Source: 10-K filed 8 May 2026, read it on SEC EDGAR.
USD 359.05bn to USD 403.43bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 359.05bn | 403.43bn | Up 12.4% |
| Net income | 3.29bn | 4.76bn | Up 44.5% |
| Total assets | 75.14bn | 82.32bn | Up 9.6% |
| Long-term debt | 5.65bn | 6.53bn | Up 15.4% |
| Cash and cash equivalents | 5.69bn | 3.98bn | Down 30.2% |
| Shareholders' equity | -2.07bn | -2.17bn | Not comparable |
Questions people ask
Did McKESSON CORPORATION's revenue grow last year?
Revenue grew 12.4%, from USD 359.05bn to USD 403.43bn in the year ended 31 Mar 2026.
Is McKESSON CORPORATION profitable?
Yes. Net income was USD 4.76bn in the year ended 31 Mar 2026. The year before: USD 3.29bn.
How much cash and debt does McKESSON CORPORATION have?
At its latest year end (31 Mar 2026), McKESSON CORPORATION reported cash and cash equivalents of USD 3.98bn and long-term debt of USD 6.53bn.
Where do these numbers come from?
From McKESSON CORPORATION's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with McKESSON CORPORATION?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Cencora, Inc.Shareholders' equity up 133.5%
- Cardinal Health, Inc.Cash and cash equivalents up 25.3%